Gilead Signs New Joint Procurement Agreement with the EC to Supply Veklury (remdesivir) for COVID-19
- The new agreement continues to enable rapid & equitable access to Veklury for COVID-19 patients in EU & EEA Countries. The agreement has a 6mos. extension option & purchase the product over the next 1yr.
- The conditional marketing authorization was based on the P-III trial to evaluate a 3-day course of Veklury in patients with COVID-19 which showed an 87% reduction in risk for the composite 1EPs of COVID-19-related hospitalization or all-cause death by 28 Day (0.7% vs 5.3%), no deaths were reported
- The agreement follows the expiration of an original JPA signed in Oct 2020. Veklury was approved or authorized for temporary use in ~50 countries globally & has established a safety profile & minimal drug interactions in diverse populations
Ref: Gilead | Image: Gilead
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.